By Ludwig Burger and Paul Arnold FRANKFURT - Sandoz plans to launch at least five additional biologic drugs, its CEO Richard Saynor said, as the generics drugs business of Switzerland'sBy Ludwig Burger and Paul Arnold
Sandoz, whose first day of trading is scheduled for Oct. 4, has previously said its development pipeline has 25 future biosimilars, cheaper versions of off-patent biologic drugs made from modified living cells, five of which it aims to bring to market over the next two years. Deutsche Bank estimates that Sandoz, which accounted for 11% of Novartis' group operating profit in 2022, is likely to have a market value of $11-$13 billion, with brokerage Berenberg expecting a $17-$26 billion valuation range.
"Whatever we launch, it's accretive to our business," he said, adding that major takeover deals were not on his agenda.